Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors.
BACKGROUND
The objective of the study was to determine the general public's level of awareness of and degree of concern about the interactions between pharmaceutical manufacturers and doctors in Melbourne. This Internet was survey administered using Survey Monkey.


METHODS
The participants in the study were employees of The Age Newspaper in Melbourne (n = 1524). Participants' self-reported levels of awareness and concern regarding pharmaceutical representatives' interactions with doctors and the resulting effect on the quality of care they receive were observed.


RESULTS
One hundred and thirty-four participants completed the questionnaire between 18 January and 8 February 2007. This was a response rate of 8.8%, and 40% reported a 'high level' of awareness of pharmaceutical marketing, whereas 59% reported believing that marketing influenced the prescribing behaviour of their doctors. Participants who reported that information provided by the pharmaceutical industry is inaccurate were significantly more likely to prefer a doctor who did not engage with pharmaceutical marketing (H(2) = 0.19, P < 0.05). There was a significant difference in perceived trustworthiness between academic sources of information and marketing based sources of information (T = 0.000, P < 0.05). The level of perceived trustworthiness of pharmaceutical marketing was significantly related to whether people wanted to be kept informed about pharmaceutical marketing activities (H(2) = 0.004, P < 0.05). Forty-eight per cent of respondents wanted to be informed about pharmaceutical marketing; 46.2% of these people would like this to be through disclosure in the form of an accredited identification system. If given a choice, 38.8% of respondents would choose a doctor who did not see pharmaceutical representatives over one that did.


CONCLUSIONS
A significant proportion of the sample surveyed was aware of pharmaceutical marketing, believed that it influenced prescribing practices and it was less trustworthy than academic sources of information, would like to be kept informed about industry interactions with their doctor and would prefer to see a doctor who did not receive visits from pharmaceutical marketing representatives.
Edwards
D
D
Centre for Human Bioethics, Melbourne, Victoria, Australia. danny.edwards@arts.monash.edu.au
Ballantyne
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D001315:Australia; D001364:Awareness; D001675:Bioethics; D016265:Conflict of Interest; D030881:Disclosure; D004345:Drug Industry / Q000941:ethics*; D004363:Drug Utilization / Q000941:ethics*; D004992:Ethics, Medical; D004994:Ethics, Pharmacy; D005260:Female; D006801:Humans; D007400:Interprofessional Relations / Q000941:ethics*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010819:Physician's Role; D010817:Physician-Patient Relations; D010818:Practice Patterns, Physicians'; D055553:Prescription Drugs; D011795:Surveys and Questionnaires; D035502:Trust; D055815:Young Adult
D055553:Prescription Drugs